Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CV Sciences ( (CVSI) ) just unveiled an announcement.
On May 14, 2026, CV Sciences reported first-quarter 2026 results showing revenue of $3.2 million, down 11.4% year over year, as restrictive federal and state regulations weighed on sales volumes, though gross margin improved to 48.9%. The company narrowed its adjusted EBITDA loss to $0.1 million, cut operating expenses by 13.3% to $1.9 million and generated 43% of net revenue from products launched since 2023, while launching its EMPOWR wellness formula and completing a debt restructuring aimed at reinforcing its financial position and enabling strategic growth initiatives.
The quarter underscored both the pressure from regulatory headwinds and CV Sciences’ efforts to reposition its portfolio toward newer products and operational efficiency. Management highlighted that the debt restructuring and cost controls are intended to improve financial flexibility and support potential acquisitions and long-term value creation, even as the company remains loss-making with a modest cash balance of $0.3 million.
Spark’s Take on CVSI Stock
According to Spark, TipRanks’ AI Analyst, CVSI is a Neutral.
The score is held down primarily by weak financial performance (recent losses, cash burn, and reduced balance-sheet resilience) and bearish technicals (negative MACD and trading below major moving averages). Corporate events provide some offset via profitability improvements and restructuring progress, but dilution/liquidity risks and the lack of dividend support keep the overall score low.
To see Spark’s full report on CVSI stock, click here.
More about CV Sciences
CV Sciences, Inc., traded on the OTCQB as CVSI, is a consumer wellness company specializing in nutraceuticals, hemp extracts and other science-backed, natural ingredients and products. Its +PlusCBD brand is a leading hemp-extract supplement line in the U.S. natural products market, complemented by non-cannabinoid +PlusHLTH supplements, Cultured Foods plant-based foods in Europe, and contract manufacturing via Elevated Softgels.
Average Trading Volume: 1,265,956
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.71M
For a thorough assessment of CVSI stock, go to TipRanks’ Stock Analysis page.